Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated May 21, 2026, titled "Audited (standalone and consolidated) financial results of the Company for quarter and financial year ended 31 March 2026".
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suraksha Diagnostic reported strong top-line growth with FY26 total income rising 23% to ₹3,136 million and EBITDA up 16% to ₹986 million. Test volumes grew 22% to 8.16 million, driven by network expansion adding 2 hubs, 11 spoke centres and 4 PPP projects. However, PAT grew only 1.4% to ₹314 million as PAT margin contracted from 12.3% to 10.1%, reflecting investment costs in new centres. Q4 saw an even sharper contrast with 25% EBITDA growth but 14% PAT decline. CEO Ritu Mittal stated that mature centres over 2 years old operate at a stable 36-37% EBITDA margin, and the company is following an 'Investing for Scale' strategy accepting short-term margin compression for long-term value creation.
The stock may face short-term pressure as profit growth lags revenue growth, but investors may find comfort in management's guidance that new centres will mature and restore margins to 36-37% levels, similar to established centres.